News Medical on MSN4d
Non-Opioid Pain Relievers Beat Opioids After Dental Surgery
Results in The Journal of American Dental Association showed the non-opioid combination provided superior pain relief during ...
Business Wire9d
A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial
Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...
Hosted on MSN7d
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...
Acsh.org1d
Does Advil Plus Tylenol Relieve Pain Better Than Vicodin? Read the Fine Print
Just what we don't need. Yet another study claiming that Advil plus Tylenol outperforms Vicodin. Lost in the sauce is that ...
Yahoo Finance8d
Xgene’s non-opioid analgesic reduces pain in Phase IIb trial
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery in a Phase IIb study[MV1] . The placebo ...
Morningstar9d
A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial
“I have not seen any analgesics showing such great efficacy ... “There is a substantial need for more efficacious, safer, non-opioid treatment for acute pain, as many patients are unable ...
Yahoo Finance9d
A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial
For those patients who required rescue analgesics, XG005 increased the time to first use of rescue by 8-fold and it reduced the total amount of opiate consumption medication by 4-fold in a high ...
Eagle-Tribune10d
A Novel Non-Opioid Multimodal Analgesic from Xgene Pharmaceutical Reduces Pain and a Need for Opioid Consumption in a Post-Surgical Pain Trial
Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) in patients ...